Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06466382 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Study acronym: OVPrecision
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 7 sitesv6
  2. Study sites: 4 to 7v5
  3. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 1 to 4
    • Primary completion date: Jan 2028 to Mar 2027
    • Study completion date: Apr 2028 to Sep 2028
    • Start date changed from estimate of Jan 2025 to Mar 31, 2025
  4. Primary completion date: Sep 2026 to Jan 2028
    • Start date: Sep 2024 to Jan 2025
    • Study completion date: Dec 2027 to Apr 2028
    v3
  5. Interventions: Carboplatin / Paclitaxel Chemotherapy (Drug), Treatment recommenation by molecular tumnor board based on tumpor profiling (Other) to Carboplatin / Paclitaxel Chemotherapy (Drug), Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling (Other)
    • Eligibility criteria expanded, about 21 words
    • Study description expanded, about 2 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Trial Details
NCT Number NCT06466382
Lead Sponsor Swiss GO Trial Group
Collaborators: Tumor Profiler Center Switzerland
Conditions
(from sponsor)		 Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
Related terms Fallopian Tube Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov